This MedLibrary.org supplementary page on Neuroleptic malignant syndrome is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
| Neuroleptic malignant syndrome Classification and external resources |
|
| ICD-10 | G21.0 |
|---|---|
| ICD-9 | 333.92 |
| DiseasesDB | 8968 |
| eMedicine | emerg/339 med/2614 ped/1581 |
| MeSH | D009459 |
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (June 2008) |
Neuroleptic malignant syndrome (NMS) is a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. It generally presents with muscle rigidity, fever, autonomic instability and cognitive changes such as delirium, and is proven on a raised creatine phosphokinase (CPK). Treatment is generally supportive.
Contents |
Causes
NMS is caused almost exclusively by antipsychotics, including all types of neuroleptic medicines along with newer antipsychotic drugs.[1] The higher the dosage, the more common the occurrence. Rapid and large increases in dosage can also trigger the development of NMS. Other drugs, environmental or psychological factors, hereditary conditions, and specific demographics may cause greater risk, but to date no conclusive evidence has been found to support this. The disorder typically develops within two weeks of the initial treatment with the drug, but may develop at any time the drug is being taken. NMS may also occur in people taking a class of drugs known as dopaminergics when the dosage is reduced (i.e. Levodopa).
Pathophysiology
The mechanism is thought to depend on decreased levels of dopamine due to:
- Dopamine receptor blockade
- Genetically reduced function of dopamine receptor D2[2]
However, the failure of D2 dopamine receptor antagonism or dopamine receptor dysfunction to fully explain the presenting symptoms and signs of NMS, as well as the occurrence of NMS with atypical antipsychotic drugs with lower D2 dopamine activity,[3] has led to the hypothesis of sympathoadrenal hyperactivity as an etiological mechanism for NMS.[4] There is also thought to be considerable overlap between malignant catatonia and NMS in their pathophysiology, the former being idiopathic and the latter being drug-induced form of the same syndrome.
Signs and symptoms
The first symptom to develop is usually muscular rigidity, followed by high fever, symptoms of instability of the autonomic nervous system such as unstable blood pressure, and changes in cognition, including agitation, delirium and coma. Other symptoms may include muscle tremors and pharyngitis. Once symptoms do appear, they rapidly progress and can reach peak intensity in as little as three days. These symptoms can last anywhere from eight hours to forty days.
A raised creatine phosphokinase (CPK) plasma concentration will be reported due to increased muscular activity. The patient may be hypertensive and suffering from a metabolic acidosis. A non-generalised slowing on an EEG is reported in around 50% of cases.
Unfortunately, symptoms are sometimes misinterpreted by doctors as symptoms of mental illness, delaying treatment.[5] NMS should be ruled out in cases of acute and significant behaviour change or deterioration in a person who has otherwise been stable for a period of time on antipsychotics, especially in situations where the dose has not been changed and the person hasn't deteriorated because of noncompliance or consumption of psychoactive substances known to worsen psychosis.
Mnemonic
A mnemonic used to remember the features of NMS is FEVER.[6]
- F - Fever
- E - Encephalopathy
- V - Vitals unstable
- E - Elevated enzymes (elevated CPK)
- R - Rigidity of muscles
Prognosis
As with most illnesses, the prognosis is best when identified early and treated aggressively. In these cases NMS is usually not fatal, although there is currently no agreement on the exact mortality rate for the disorder. Studies have given the disorder a mortality rate as low as 5% and as high as 76%, although most studies agree that the correct percentage is in the lower spectrum, perhaps 10–15%. Re-introduction to the drug that originally caused NMS to develop may also trigger a recurrence, although in most cases it does not.
Treatment
Although treatment is not always necessary, it will help to cure the disease and prevent fatal developments from occurring. The first step in treatment is generally to remove the patient from any neuroleptic or antipsychotic drugs being taken and to treat fever aggressively. Many cases require intensive care, or some kind of supportive care at the minimum. Depending on the severity of the case, patients may require other treatments to contend with specific effects of the disorder. These include circulatory and ventilatory support, the drugs dantrolene sodium, bromocriptine, apomorphine and electroconvulsive therapy (ECT) if medication fails. Benzodiazepines may also be of great benefit.
NMS and serotonergic syndrome
The clinical features of NMS and serotonergic syndrome are very similar. This can make differentiating them very difficult.[7]
Features, classically present in NMS, that are useful for differentiating the two syndromes are:[8]
- Fever
- Muscle rigidity
- Laboratory Values (WBC & CK)
History
NMS was known about as early as 1956, shortly after the introduction of the first phenothiazines, and is derived from the French syndrome malin des neuroleptiques.[9]
References
- ^ Theodore I. Benzer, MD, PhD (2005). "Neuroleptic Malignant Syndrome". Emedicine.
- ^ Mihara K, Kondo T, Suzuki A, et al (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet. 117 (1): 57–60. doi:. PMID 12555236.
- ^ Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). "Neuroleptic malignant syndrome and atypical antipsychotic drugs". J. Clin. Psychiatry 65 (12): 1722–3. PMID 15119907.
- ^ Gurrera RJ (1999). "Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome". Am. J. Psychiatry 156 (2): 169–80. PMID 9989551.
- ^ Stacy Milbouer, "Quest for the truth", Nashua Telegraph http://www.nashuatelegraph.com/apps/pbcs.dll/article?AID=/20050424/NEWS01/104240081
- ^ Identify neuroleptic malignant syndrome. schizophrenia.com URL:http://www.schizophrenia.com/sznews/archives/002054.html. Accessed: July 2, 2006.
- ^ Christensen V, Glenthøj B (2001). "[Malignant neuroleptic syndrome or serotonergic syndrome]". Ugeskr Laeger 163 (3): 301–2. PMID 11219110.
- ^ Birmes P, Coppin D, Schmitt L, Lauque D (2003). "Serotonin syndrome: a brief review.". CMAJ 168 (11): 1439–42. PMID 12771076. Full Free Text.
- ^ Friedberg JM. Neuroleptic malignant syndrome. URL: http://www.idiom.com/~drjohn/biblio.html. Accessed: July 3, 2006.
External links
- NMSIS - Neuroleptic Malignant Syndrome Information Service
- Canadian Movement Disorder Group - cmdg.org.
- NMS - counsellingresource.com.
- NINDS Neuroleptic Malignant Syndrome Information Page - NIH.
- NMS - currentpsychiatry.com
- Instructional Video for Detection of NMS - Medical Instructional Media.
|
|||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 10 August 2008, at 18:02.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Neuroleptic malignant syndrome".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.